Risk factors for acute exacerbation of idiopathic pulmonary fibrosis-extended analysis of pirfenidone trial in Japan

Respiratory Investigation

Volumn 53, Issue 6, 2015, Pages 271-278

  Kondoh, Yasuhiro ^a   Taniguchi, Hiroyuki ^a   Ebina, Masahito ^b   Azuma, Arata ^c   Ogura, Takashi ^d   Taguchi, Yoshio ^e   Suga, Moritaka ^f   Takahashi, Hiroki ^g   Nakata, Koichiro ^h   Sugiyama, Yukihiko ⁱ   Kudoh, Shoji ^c,j   Nukiwa, Toshihiro ^b,k  

^a TOSEI GENERAL HOSPITAL   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^e TENRI HOSPITAL   (Japan)

^f SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^g SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^h Nakata Clinic ^*  (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

^j Japan Anti Tuberculosis Association   (Japan)

^k South Miyagi Medical Center   (Japan)

more..

Author keywords

Absolute decline in VC; Acute exacerbation; Idiopathic pulmonary fibrosis (IPF); Relative decline in VC; Risk factor

Indexed keywords

PIRFENIDONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ADULT; AGED; ALVEOLAR TO ARTERIAL OXYGEN PRESSURE DIFFERENCE; ARTICLE; BLOOD GAS PARAMETERS; CLINICAL ARTICLE; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FIBROSING ALVEOLITIS; HUMAN; JAPAN; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; VITAL CAPACITY; ACUTE DISEASE; IDIOPATHIC PULMONARY FIBROSIS; LUNG ALVEOLUS; METABOLISM; MULTIVARIATE ANALYSIS; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

ACUTE DISEASE; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXYGEN CONSUMPTION; PROPORTIONAL HAZARDS MODELS; PULMONARY ALVEOLI; PYRIDONES; RISK FACTORS; VITAL CAPACITY;

EID: 84954198075     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2015.04.005     Document Type: Article

References (28)

1. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
2. Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993, 103:1808-1812.
3. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176:636-643.
4. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011, 37:356-363.
5. Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffus Lung Dis 2010, 27:103-110.
6. Ley B, Collard HR, King TE Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:431-440.
7. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047.
8. King TE, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177:75-81.
9. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829.
10. Noble PW, Albera C, Bradford WZ, et al. CAPACITY Study Group Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377(9779):1760-1769.
11. King TE, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:92-99.
12. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087.
13. Noth I, Anstrom KJ, Calvert SB, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network (IPF net). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 186:88-95.
14. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664.
15. Taniguchi H, Kondoh Y. Revised criteria for acute exacerbation of idiopathic pulmonary fibrosis. The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease; 2004. p. 114-9.
16. Akaike H. Information theory and an extension of the maximum principle. In: Proceedings of the 2nd International Symposium on Information Theory. Akademia Kiado, Budapest; 1973. p. 267-81.
17. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531-537.
18. Collard HR, King TE, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-542.
19. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:543-548.
20. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005, 171:639-644.
21. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:459-466.
22. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012, 67:407-411.
23. Atkins CP, Loke YK, Wilson AM. Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials. Respir Med 2014, 108(2):376-387.
24. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 180:167-175.
25. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis. PLoS One 2007, 2:e482.
26. King TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001, 164:1171-1181.
27. Azuma A, Hagiwara A, Kudoh S. Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients. Am J Respir Crit Care Med 2008, 177:1397-1398.
28. Collard HR, Yow E, Richeldi L., et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013, 14:73.